Trimester‐Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study
Liver International · 2026
DOI: 10.1111/liv.70471 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Liver International, 2026. Verfasst von Lei Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Pregnancy Outcome, Fatty Liver, Pregnancy Complications, Pregnancy Trimesters. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Capital Health Research and Development of Special Fund, Sino-German Mobility Programme.
Abstract (Originalsprache)
Background and Aims Steatotic liver disease (SLD) is increasingly identified in pregnant populations. However, its associations with adverse pregnancy outcomes (APOs) in relation to specific trimesters remain unclear. This study aimed to evaluate the trimester‐specific associations between SLD and APOs.
Methods
This study included 3806 pregnant women from Beijing Friendship Hospital. Hepatic ultrasonography was performed to assess SLD status during the first (T1) and third (T3) trimesters. Associations between SLD and APOs were assessed using logistic regression.
Results
The prevalence of SLD among pregnant women was 10.27%, varying across trimesters. Persistent SLD (present in both T1 and T3) demonstrated positive associations with overall APOs (OR = 1.728, 95% CI: 1.202–2.502, p = 0.003), including pregnancy‐associated hypertension (OR = 1.742; 95% CI: 1.019–2.916; p = 0.038), preterm birth (OR = 2.552, 95% CI: 1.019–5.965, p = 0.037), and large‐for‐gestational‐age neonates (OR = 1.762, 95% CI: 1.080–2.820, p = 0.020). T1 SLD (OR = 1.737, 95% CI: 1.128–2.700, p = 0.013) and persistent SLD (OR = 1.821, 95% CI: 1.282–2.600, p < 0.001) were both associated with a higher risk of caesarean section. Notably, T3 SLD was significantly associated with postpartum haemorrhage (OR = 2.154; 95% CI: 1.025–4.078; p = 0.028). A marginal association was observed between pregnancy‐associated hypertension and T3 SLD (OR = 2.024; 95% CI: 0.965–3.876; p = 0.045).
Conclusion
Persistent SLD in pregnancy is associated with an increased risk of APOs, trimester‐specific assessment of SLD may facilitate risk stratification and inform clinical management. Further studies are warranted to evaluate whether lifestyle interventions can mitigate these risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Maternal and Child Health, School of Public Health, Peking University, Beijing, China.
- Department of Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
- National Health Commission Key Laboratory of Reproductive Health, Beijing, China.
ORCID-Profile: Shuhan Yang, Antje Hebestreit, Yan Long, Hui Wang
Förderung
- Capital Health Research and Development of Special Fund
- Sino-German Mobility Programme
Zitieren
APA
Yang, L., Yang, S., Wang, Y., Hebestreit, A., Wang, M., Yang, Y., Wu, Y., Long, Y., & Wang, H. (2026). Trimester‐Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study. Liver International. https://doi.org/10.1111/liv.70471
Vancouver
Yang L, Yang S, Wang Y, Hebestreit A, Wang M, Yang Y, et al. Trimester‐Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study. Liver International. 2026. doi:10.1111/liv.70471
BibTeX
@article{Yang2026,
author = {Yang, Lei and Yang, Shuhan and Wang, Youxin and Hebestreit, Antje and Wang, Mingyue and Yang, Yifan and Wu, Yuying and Long, Yan and Wang, Hui},
title = {Trimester‐Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70471}
}
EUVIMED